When did Integra LifeSciences report Q2 2025 earnings?

Integra LifeSciences (IART) reported Q2 2025 earnings on July 31, 2025 before market open.

What were Integra LifeSciences's Q2 2025 revenue and EPS?

Integra LifeSciences reported revenue of $415.6M and eps of $0.45 for Q2 2025.

Did Integra LifeSciences beat estimates in Q2 2025?

Revenue beat the consensus estimate of $414.3M by $1.3M. EPS beat the consensus estimate of $0.43 by $0.02.

How did Integra LifeSciences's Q2 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue declined 0.6% from $418.2M a year earlier and eps declined 28.6% from $0.63.

Where can I find Integra LifeSciences's Q2 2025 SEC filings?

You can read the 10-Q periodic report (0000917520-25-000074) directly on SEC EDGAR. The filing index links above go to sec.gov.

Integra LifeSciences IART Q2 2025 earnings

Reported July 31, 2025 · Before market open

Revenue$415.6MBeat by $1.3M

EPS$0.45Beat by $0.02

Revenue estimate$414.3M

EPS estimate$0.43

Next report

Jul 29, 2026 (Today)

Revenue estimate$417.5M

EPS estimate$0.48

View report

Financials

Q2 2025

Income statement

See full

Revenue$415.6M-0.6%

Gross profit$209.3M-7.3%

Operating income-$512.7M-16,826%

Net income-$484.1M-3,803%

EPS (diluted)-$6.31-3,844%

Balance sheet

See full

Cash & equivalents$217.9M+1.2%

Total debt$1.9B+39.1%

Total equity$1.0B-32.3%

Total assets$3.7B-10.0%

Cash flow

See full

Operating cash flow$8.9M-77.9%

CapEx$20.1M-32.2%

Free cash flow-$11.2M-205%

Valuation & ratios

Valuation

as of 06/30/25

See full

Market cap$922.44M-59.3%

Enterprise value$2.61B-23.7%

P/S0.6×-0.9×

Profitability

See full

Gross margin52.6%-3.4pp

Operating margin-30.9%-34.9pp

Returns & leverage

See full

Debt / equity1.8×+0.9×

Current ratio1.2×-2.2×

Segments

By product

See full

Neurosurgery$209.0M+1.7%

Wound Reconstruction$84.7M-3.4%

Instruments$53.1M-2.7%

ENT$41.9M+0.4%

Private Label$26.9M-6.3%

By geography

See full

Asia Pacific$47.7M+3.9%

Europe$42.6M+4.7%

Rest of World$19.0M—

By segment

See full

Specialty Surgery$304.0M—

Tissue Reconstruction$111.6M—

Versus estimates

Revenue

Q1 2026$391.9MBeat by $10.1M Q4 2025$434.9MBeat by $5.3M Q3 2025$402.1MMiss by $27.6M

Q2 2025$415.6MBeat by $1.3M

Q1 2025$382.7MMiss by $19.9M Q4 2024$442.6MBeat by $30.9M

Diluted EPS

Q1 2026$0.54Beat by $0.13 Q4 2025$0.83Beat by $0.04 Q3 2025$0.54Beat by $0.11

Q2 2025$0.45Beat by $0.02

Q1 2025$0.41Miss by $0.02 Q4 2024$0.97Beat by $0.11

Ask the moment Integra LifeSciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Integra LifeSciences report Q2 2025 earnings?: Integra LifeSciences (IART) reported Q2 2025 earnings on July 31, 2025 before market open.
What were Integra LifeSciences's Q2 2025 revenue and EPS?: Integra LifeSciences reported revenue of $415.6M and eps of $0.45 for Q2 2025.
Did Integra LifeSciences beat estimates in Q2 2025?: Revenue beat the consensus estimate of $414.3M by $1.3M. EPS beat the consensus estimate of $0.43 by $0.02.
How did Integra LifeSciences's Q2 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue declined 0.6% from $418.2M a year earlier and eps declined 28.6% from $0.63.
Where can I find Integra LifeSciences's Q2 2025 SEC filings?: You can read the 10-Q periodic report (0000917520-25-000074) directly on SEC EDGAR. The filing index links above go to sec.gov.